Eric Lefkofsky Sells 166,250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total value of $7,763,875.00. Following the completion of the sale, the chief executive officer directly owned 8,808,533 shares in the company, valued at $411,358,491.10. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

NASDAQ TEM traded down $0.82 during trading hours on Friday, hitting $50.47. The company had a trading volume of 11,745,909 shares, compared to its average volume of 5,693,381. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The business has a fifty day simple moving average of $48.69 and a 200-day simple moving average of $58.25. The firm has a market cap of $9.06 billion, a P/E ratio of -29.34 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period last year, the company earned ($0.24) earnings per share. The firm’s revenue for the quarter was up 36.1% on a year-over-year basis. Equities analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. lowered their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of Tempus AI in a report on Wednesday, March 11th. BTIG Research lowered their price target on Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wall Street Zen lowered Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Guggenheim lowered their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $68.64.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after acquiring an additional 817,014 shares during the period. ARK Investment Management LLC grew its holdings in Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after acquiring an additional 381,816 shares during the period. GC Wealth Management RIA LLC acquired a new position in Tempus AI during the fourth quarter worth about $399,267,000. Sumitomo Mitsui Trust Group Inc. grew its holdings in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. grew its holdings in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.